Login / Signup

Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.

Antoine AdenisAmit S KulkarniGustavo C GirottoChristelle De La FouchardièreHelene SenellartHanneke Wilma Marlies van LaarhovenWasat MansoorRaed Al-RajabiJosephine NorquistMayur AmonkarShailaja SuryawanshiPooja BhagiaJean-Philippe Metges
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
In patients with advanced EC, pembrolizumab monotherapy and chemotherapy maintained HRQoL in patients with SCC, CPS ≥ 10, and CPS ≥ 10 SCC.
Keyphrases
  • locally advanced
  • advanced non small cell lung cancer
  • combination therapy
  • open label
  • chemotherapy induced
  • clinical trial
  • radiation therapy
  • phase ii
  • randomized controlled trial
  • tyrosine kinase